MedTrace Logo

Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women

NCT04209530 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2021-10-07

Study results available
· View outcomes & findings →

Summary

This is a single center, open-label, Phase 2a study to assess the photonumeric scale, morphological, and histopathological changes associated with Collagenase Clostridium Histolyticum (CCH) in adult women with moderate or severe Edematous Fibrosclerotic Panniculopathy (EFP).

Conditions

  • Cellulite
  • Edematous Fibrosclerotic Panniculopathy (EFP)

Interventions

DRUG

EN3835

Collagenase Clostridium Histolyticum (CCH)

Sponsors & Collaborators

  • Endo Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Ashley Dayoub · Endo Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-20
Primary Completion
2020-07-23
Completion
2020-10-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04209530 on ClinicalTrials.gov